Your browser doesn't support javascript.
loading
[Bullous skin diseases].
Kaae, Jeanette; Bech, Rikke; Taudorf, Elisabeth Hjardem; Beck, Shiva; Vestergaard, Christian; Ring, Hans Christian; Jemec, Gregor B.
Affiliation
  • Kaae J; Dermatologisk Afdeling, Sjællands Universitetshospital, Roskilde.
  • Bech R; Hud- og Kønssygdomme, Aarhus Universitetshospital.
  • Taudorf EH; Dermatologisk Afdeling, Sjællands Universitetshospital, Roskilde.
  • Beck S; Dermatologisk Afdeling, Sjællands Universitetshospital, Roskilde.
  • Vestergaard C; Hud- og Kønssygdomme, Aarhus Universitetshospital.
  • Ring HC; Dermato-Venerologisk Afdeling og Videnscenter for Sårheling, Københavns Universitetshospital - Bispebjerg Hospital.
  • Jemec GB; Dermatologisk Afdeling, Sjællands Universitetshospital, Roskilde.
Ugeskr Laeger ; 184(41)2022 10 10.
Article in Da | MEDLINE | ID: mdl-36254827
ABSTRACT
This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Skin Diseases, Vesiculobullous / Pemphigus Limits: Humans Language: Da Journal: Ugeskr Laeger Year: 2022 Document type: Article
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Autoimmune Diseases / Skin Diseases, Vesiculobullous / Pemphigus Limits: Humans Language: Da Journal: Ugeskr Laeger Year: 2022 Document type: Article